Chemical stock which is the leading manufacturer of bromine and lithium-based specialty chemicals jumped upto 9 percent in the day’s trade following Q3FY25 results with a 844 percent jump in Net Profits.
Price Action
With a market capitalization of Rs. 5,476 Crores, the shares of Neogen Chemicals Limited were trading at Rs. 2,076 per equity share, up 5 percent from its previous day’s close price of Rs. 1,985.
Q3 FY25 Results
Its Revenue from operations grew by 23 percent YoY from Rs. 164.44 Crores in Q3FY24 to Rs. 201.43 Crores in Q3FY25 and it grew by 5 percent QoQ from Rs. 193.36 Crores in Q2FY25 to Rs. 201.43 Crores in Q3FY25.
Its Net Profit grew by 844 percent YoY from Rs. 1.06 Crores in Q3FY24 to Rs. 10.01 Crores in Q3FY25 and it declined by 7 percent QoQ from Rs. 10.96 Crores in Q2FY25 to Rs. 10.01 Crores in Q3FY25.
Its Net Profit Margin increased from 0.63 percent in Q3FY24 to 4.94 percent in Q3FY25, while the EPS doubled from Rs. 0.41 to Rs. 3.80 per equity share.
About the Company
Neogen Chemicals Limited is engaged in the business of manufacturing and supplying of specialty chemicals that are used in pharmaceutical, engineering and agro-chemical industries.
It manufactures specialty bromine and lithi, with business segments including Organic Chemicals and Inorganic Chemicals. These chemicals are utilized in various industries, such as pharmaceuticals, agrochemicals, engineering, electronics, polymers, water treatment, construction, aroma chemicals, flavors and fragrances, and specialty polymers.
The capex plans stand at Rs. 1,500 Crores with peak revenue potential ranging from Rs. 2,500-2,950 Crores. It involves Electrolyte, Lithium Electrolyte salts & Additives manufacturing plants with a capacity of 32,000MT and 5,000MT respectively.
Neogen Chemicals Limited is the leading manufacturer of bromine and lithium-based specialty chemicals, with 4 manufacturing facilities and 2 R&D centers and a product portfolio of 246. It also has a strong customer base with well-known players like Sun Pharmaceuticals, Thermax, Voltas, Piramal, Divis Laboratories, and many others.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
